- Home
- NERV vs AOMR Comparison
NERV vs AOMR Comparison
Compare NERV & AOMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NERV | AOMR |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.6M | 218.7M |
| IPO Year | 2014 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NERV | AOMR |
|---|---|---|
| Price | $7.85 | $8.18 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $7.00 | ★ $11.31 |
| AVG Volume (30 Days) | ★ 160.1K | 89.4K |
| Earning Date | 07-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 15.38% |
| EPS Growth | N/A | ★ 53.85 |
| EPS | N/A | ★ 1.80 |
| Revenue | ★ $41,175,600.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $0.83 |
| P/E Ratio | ★ N/A | $4.62 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.15 | $7.36 |
| 52 Week High | $12.46 | $10.21 |
Technical Indicators
Market Signals| Indicator | NERV | AOMR |
|---|---|---|
| Relative Strength Index (RSI) | 67.71 | 31.01 |
| Support Level | $5.34 | $8.18 |
| Resistance Level | $12.46 | $8.91 |
| Average True Range (ATR) | 0.65 | 0.22 |
| MACD | 0.07 | -0.03 |
| Stochastic Oscillator | 79.94 | 9.09 |
Price Performance
Historical ComparisonAbout NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About AOMR Angel Oak Mortgage REIT Inc.
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in the first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation across interest rates and credit cycles.